Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

(2014) Alix E. Seif et al.   PEDIATRIC BLOOD & CANCER

Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: A longitudinal study

(2013) Tanya Renae Brown et al.   PEDIATRIC BLOOD & CANCER

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

(2012) S. E. Lipshultz et al.   PEDIATRICS

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

(2011) Lynda M. Vrooman et al.   EUROPEAN JOURNAL OF CANCER

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children

(2009) Arturo Muñoz et al.   Clinical & Translational Oncology

Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J

(2009) Yukihide Iwamoto et al.   JOURNAL OF ORTHOPAEDIC SCIENCE

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY